Report copyright - COVID-19 Treatment and Vaccine Tracker · Phase 2 primary trial ends April 30, 2020 BioCentury 9 leronlimab (PRO 140), a CCR5 antagonist N/A Treatment of HIV/ AIDS, Graft versus Host
Please pass captcha verification before submit form